Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A designed TLR4/MD-2 complex to capture LPS.

Katharina Brandl1, Thomas Glück, Pia Hartmann

  • 1Department of Internal Medicine I, University of Regensburg, Regensburg, Germany. katharina.brandl@klinik.uni-regensburg.de

Journal of Endotoxin Research
|September 24, 2005
PubMed
Summary

Researchers developed novel soluble Toll-like receptor 4 (TLR4) fusion proteins to block lipopolysaccharide (LPS) activity. These TLR4-MD-2 complexes show potential as a new therapeutic strategy for sepsis by neutralizing TLR4-activating ligands.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogen patterns in viral ARDS on V-V ECMO: a single-center experience.

Infection·2026
Same author

SARS-CoV-2 evolution enhances endocytic uptake while preserving TMPRSS2-dependent fusion.

Frontiers in immunology·2026
Same author

Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.

German medical science : GMS e-journal·2025
Same author

Back to the wildtype: SARS-CoV-2 evolution in critically ill patients with severe lung failure.

Infection·2025
Same author

[Tuberculosis - New perspectives in diagnosis and treatment].

Deutsche medizinische Wochenschrift (1946)·2025
Same author

[S3 guideline on sepsis-prevention, diagnosis, therapy, and follow-up care-update 2025].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2025

Area of Science:

  • Immunology and Molecular Biology
  • Receptor Signaling Pathways

Background:

  • Toll-like receptors (TLRs) are crucial for innate immunity against microbial pathogens.
  • Toll-like receptor 4 (TLR4) signaling mediates responses in infectious and inflammatory diseases, including sepsis.
  • Modulating TLR4 signaling through soluble receptors offers a potential therapeutic avenue.

Purpose of the Study:

  • To develop and characterize novel soluble fusion proteins targeting mouse TLR4 signaling.
  • To investigate the potential of these molecules in neutralizing lipopolysaccharide (LPS) activity.
  • To explore therapeutic applications for sepsis by blocking TLR4 activation.

Main Methods:

  • Production of N-terminally Flag-tagged mouse recombinant soluble TLR4-IgGFc (T4Fc) and MD-2 proteins in Drosophila S2 cells.

Related Experiment Videos

  • Testing inhibitory activity against pro-inflammatory cytokine synthesis in LPS-stimulated mouse macrophage RAW 264.7 cells.
  • Construction and functional assessment of a designer molecule (LPS-Trap) by fusing MD-2 to soluble TLR4.

    • Main Results:

    • The T4Fc/MD-2 complex effectively blocked lipopolysaccharide (LPS)-induced pro-inflammatory cytokine synthesis in vitro.
    • The engineered LPS-Trap molecule also significantly inhibited TNF production in LPS-stimulated cells.
    • Both the T4Fc/MD-2 complex and LPS-Trap demonstrated in vitro efficacy in blocking TLR4-activating ligands.

    Conclusions:

    • Soluble TLR4-MD-2 complexes and the LPS-Trap are effective inhibitors of LPS activity in vitro.
    • These novel molecules represent a promising therapeutic strategy for sepsis by neutralizing TLR4 activation.
    • Further in vivo studies are warranted to validate their therapeutic potential in sepsis models.